Information  X 
Enter a valid email address

Company Name matching 'DBV Technologies S.A'

Date
Time Source
Company
Announcement
05 Mar 2019 9:10 pm GNW   DBV Technologies S.A. DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update
  6:30 am GNW   DBV Technologies S.A. DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors
01 Mar 2019 6:30 am GNW   DBV Technologies S.A. DBV Technologies to Attend Upcoming Investor Conferences
22 Feb 2019 4:00 pm GNW   DBV Technologies S.A. DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
13 Feb 2019 9:00 pm GNW   DBV Technologies S.A. DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
08 Feb 2019 3:00 pm GNW   DBV Technologies S.A. DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company
04 Feb 2019 9:00 pm GNW   DBV Technologies DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019
01 Feb 2019 6:30 am GNW   DBV Technologies DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference
03 Jan 2019 6:30 am GNW   DBV Technologies DBV Technologies Expands and Strengthens Leadership Team
19 Dec 2018 10:00 pm GNW   DBV Technologies DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age
12 Dec 2018 6:30 am GNW   DBV Technologies DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018
20 Nov 2018 6:30 am GNW   DBV Technologies DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
16 Nov 2018 6:30 am GNW   DBV Technologies DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
09 Nov 2018 6:31 am GNW   DBV Technologies DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting
30 Oct 2018 6:30 am GNW   DBV Technologies DBV Technologies Reports September 30, 2018 Cash Position
26 Oct 2018 6:30 am GNW   DBV Technologies DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers
25 Sep 2018 6:30 am GNW   DBV Technologies DBV Technologies to Present at the Cantor Global Healthcare Conference
12 Sep 2018 6:30 am GNW   DBV Technologies DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
07 Sep 2018 6:30 am GNW   DBV Technologies DBV Technologies : Reports First Half 2018 Financial Results
05 Sep 2018 6:30 am GNW   DBV Technologies DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI
31 Aug 2018 6:30 am GNW   DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
27 Jul 2018 6:30 am GNW   DBV Technologies DBV Technologies Reports June 30, 2018 Cash Position
26 Jul 2018 6:30 am GNW   DBV Technologies DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
22 Jun 2018 9:00 pm GNW   DBV Technologies DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
05 Jun 2018 6:30 am GNW   DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
01 Jun 2018 6:30 am GNW   DBV Technologies DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting
29 May 2018 6:30 am GNW   DBV Technologies DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018
16 May 2018 6:30 am GNW   DBV Technologies DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
14 May 2018 1:31 pm GNW   DBV Technologies DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week
08 May 2018 6:30 am GNW   DBV Technologies DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting
01 May 2018 6:30 am GNW   DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
03 Apr 2018 6:30 am GNW   DBV Technologies DBV Technologies to Attend the 11th Kempen Life Sciences Conference
26 Mar 2018 9:01 pm GNW   DBV Technologies DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
23 Mar 2018 8:01 pm GNW   DBV Technologies DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
21 Mar 2018 7:00 am GNW   DBV Technologies DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
20 Mar 2018 8:01 pm GNW   DBV Technologies DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
16 Mar 2018 8:30 pm GNW   DBV Technologies DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F
14 Mar 2018 6:30 am GNW   DBV Technologies DBV Technologies Reports Full Year 2017 Financial Results
07 Mar 2018 6:30 am GNW   DBV Technologies DBV Technologies to Present at the Barclays Global Healthcare Conference
26 Feb 2018 10:05 pm GNW   DBV Technologies DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
  10:00 pm GNW   DBV Technologies DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients
20 Feb 2018 6:30 am GNW   DBV Technologies DBV Technologies Reports December 31, 2017 Cash Position
14 Feb 2018 6:30 am GNW   DBV Technologies DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut
12 Feb 2018 2:00 pm GNW   DBV Technologies DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin
01 Feb 2018 6:30 am GNW   DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
16 Jan 2018 6:30 am GNW   DBV Technologies Half-Year Report on DBV Technologies Liquidity Contract with Natixis
03 Jan 2018 6:30 am GNW   DBV Technologies DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference
04 Dec 2017 6:30 am GNW   DBV Technologies DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E...
28 Nov 2017 6:30 am GNW   DBV Technologies DBV Technologies to Attend Citi's 2017 Global Healthcare Conference
14 Nov 2017 4:30 pm GNW   DBV Technologies DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association
31 Oct 2017 6:30 am GNW   DBV Technologies DBV Technologies Reports September 30, 2017 Cash Position
20 Oct 2017 10:15 pm GNW   DBV Technologies DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
12 Oct 2017 6:30 am GNW   DBV Technologies DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut
01 Sep 2017 6:30 am GNW   DBV Technologies DBV Technologies to Attend Upcoming Investor Conferences
29 Aug 2017 6:30 am GNW   DBV Technologies DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut
02 Aug 2017 6:30 am GNW   DBV Technologies DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age
28 Jul 2017 6:30 am GNW   DBV Technologies DBV Technologies Reports First Half 2017 Financial Results
17 Jun 2017 7:30 am GNW   DBV Technologies DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress
15 Jun 2017 9:30 pm GNW   DBV Technologies DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t